TKNO stock icon

Alpha Teknova
TKNO

$1.92
42.96%

Market Cap: 102M

 

About: Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its product offerings include pre-poured media plates for cell growth and cloning, liquid cell culture media and supplements for cellular expansion, and molecular biology reagents for sample manipulation, resuspension, and purification. It derives maximum revenue from United States.

Employees: 211

0
Funds holding %
of 6,702 funds
Analysts bullish %
0
News positive %
of 4 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

100% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 7

0.87% more ownership

Funds ownership: 13.81% [Q4 2023] → 14.68% (+0.87%) [Q1 2024]

0% more funds holding

Funds holding: 31 [Q4 2023] → 31 (+0) [Q1 2024]

0% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 3

26% less capital invested

Capital invested by funds: $21M [Q4 2023] → $15.6M (-$5.41M) [Q1 2024]

Research analyst outlook

2 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$5
160%
upside
Avg. target
$10
421%
upside
High target
$15
681%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
Stephens & Co.
Jacob Johnson
160%upside
$5
Overweight
Reiterated
10 Jul 2024
Stephens & Co.
Jacob Johnson
681%upside
$15
Overweight
Reiterated
14 May 2024

Financial journalist opinion

Based on 4 articles about TKNO published over the past 30 days